Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Recruiting now

Conditions studied: Prurigo Nodularis

In brief

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Key facts

Study ID

NCT06988618

Run by

Galderma R&D

People needed

600

Starts

2025-08-11

Expected to finish

2027-11-30

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
• Participants greater than or equal to (>=) 18 years of age.
• Participants who signed the written informed consent form (ICF).

You may not qualify if…

• Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
• Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
• Participants who received nemolizumab previously.
• Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Where it is running

• Galderma Investigational Tracker Site # 6172 — Berlin, Germany (enrolling)
• Galderma Investigational Site # 6371 — Oberursel, Germany (enrolling)
• Galderma Investigational Site # 6373 — Mainz, Germany (enrolling)
• Galderma Investigational Site # 6386 — Bielefeld, Germany (enrolling)
• Galderma Investigational Site # 7055 — Portsmouth, New Hampshire, United States (enrolling)
• Galderma Investigation Site # 6367 — Rostock, Mecklenburg-Vorpommern, Germany (enrolling)
• Galderma Investigational Site # 6385 — Berlin, Germany (enrolling)
• Galderma Investigational Site # 6384 — Koblenz, Germany (enrolling)
• Galderma Investigational Site # 6836 — Fountain Valley, California, United States (enrolling)
• Galderma Investigational Site # 8224 — Fremont, California, United States
• Galderma Investigational Site # 7078 — Miami, Florida, United States
• Galderma Investigational Site # 7053 — Waterford, Michigan, United States
• Galderma Investigational Site # 7070 — North Miami Beach, Florida, United States
• Galderma Investigational Site # 7091 — Tampa, Florida, United States
• Galderma Investigational Site # 7063 — Cutler Bay, Florida, United States
• Galderma Investigational Site # 7060 — Phoenix, Arizona, United States
• Galderma Investigational Site # 7087 — Coral Gables, Florida, United States
• Galderma Investigational Site # 7066 — Auburn Hills, Michigan, United States
• Galderma Investigational Site # 7065 — Brighton, Massachusetts, United States
• Galderma Investigational Site # 7059 — Fairfield, Connecticut, United States
• Galderma Investigational Site # 7071 — Caledonia, Michigan, United States
• Galderma Investigational Site # 7072 — Troy, Michigan, United States
• Galderma Investigational Site # 7074 — Corona, California, United States
• Galderma Investigational Site # 7057 — Lee's Summit, Missouri, United States
• Galderma Investigational Site # 7068 — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.